tbResList Print — ORM Ormeloxifene (Centchroman)

Filters: qv=497, qv2=%, rfv=%

Product

ORM Ormeloxifene (Centchroman)
Description: <p><b>Ormeloxifene (Centchroman)</b> — Nonsteroidal selective estrogen receptor modulator (SERM) originally developed as a once-weekly oral contraceptive. Ormeloxifene exhibits tissue-selective estrogenic and anti-estrogenic effects, including strong anti-estrogenic activity in breast tissue and modulation of estrogen signaling in the endometrium.</p>

<p><b>Drug class:</b> Selective Estrogen Receptor Modulator (SERM) / nonsteroidal anti-estrogen / repurposed anticancer drug.</p>

<p><b>Primary clinical uses:</b> Oral contraception, mastalgia, fibroadenoma, and selected gynecologic disorders. Ormeloxifene has been used clinically in India for decades.</p>

<p><b>Cancer relevance:</b> Moderate to strong preclinical evidence with limited clinical evidence. Ormeloxifene has demonstrated antiproliferative, pro-apoptotic, anti-invasive, and antimetastatic effects in breast, ovarian, head-and-neck, pancreatic, prostate, and hematologic cancer models. Early clinical studies in advanced breast cancer also reported objective responses in a subset of patients.</p>

<p><b>Typical mechanisms:</b> Estrogen receptor signaling modulation; proliferation ↓; cell-cycle progression ↓; apoptosis ↑; BAX ↑; BCL2 ↓; caspase activation ↑; PI3K/AKT signaling ↓; MAPK/ERK signaling ↓; NF-kB signaling ↓; migration ↓; invasion ↓; EMT ↓. Mechanisms vary by tumor type and may include estrogen-receptor-independent effects.</p>

<p><b>Estrogen receptor relevance:</b> Ormeloxifene is a SERM rather than a pure estrogen receptor antagonist. Its effects are tissue-selective and should not be interpreted as universal ESR1/ESR2 inhibition.</p>

<p><b>Pharmacokinetics:</b> Ormeloxifene has a long elimination half-life, approximately 168 hours, supporting once-weekly contraceptive dosing.</p>

<p><b>Recommended product classification:</b> Drug — SERM / Repurposed Anticancer Drug.</p>

Pathway results for Effect on Cancer / Diseased Cells

Core Metabolism/Glycolysis(tgid=4) ⓘ

Alanine↓, 1,   Glycine↓, 1,   Glycolysis↓, 1,   PKM2↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

Ki-67↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

Ki-67↓, 1,   TumCG↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

Hif1a↓, 1,  

Barriers & Transport(tgid=15) ⓘ

EPR↑, 1,   GLUT1↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 1,   eff↑, 1,   Synergy↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   toxicity↓, 1,   TumW↓, 1,  
Total Targets: 16

Pathway results for Effect on Normal Cells

Total Targets: 0

Research papers

Year Title Authors PMID Link Flag
2022Diindolylmethane Promotes Metabolic Crisis and Enhances the Efficacy of Centchroman in Breast Cancer: A 1H NMR-Based ApproachDhanamjai PentaPMC9713897https://pmc.ncbi.nlm.nih.gov/articles/PMC9713897/0